Literature DB >> 26804119

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with liver involvement.

Yaniv Berger1, Samantha Aycart1, Parissa Tabrizian1, Yahel Agmon1, John Mandeli2, Marina Heskel1, Spiros Hiotis1, Umut Sarpel1, Daniel M Labow1.   

Abstract

BACKGROUND: We examined outcomes of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) combined with liver resection.
METHODS: All patients undergoing CRS/HIPEC between 2007 and 2014 were retrospectively reviewed: patients who underwent synchronous liver resection (group 1) were compared with those who did not (group 2) in terms of perioperative and long-term results.
RESULTS: Group 1 included 103 patients with colorectal cancer (CRC, n = 28), appendiceal cancer (n = 34), and other malignancies. Compared with group 2 (n = 166), group 1 had higher number of organs resected, increased intraoperative blood loss, and longer hospital stay (all P ≤ 0.004) but similar major morbidity (24.3% vs. 18.1%, P = 0.22) and perioperative mortality rates. Two patients from group 1 developed liver resection-related complications. A comparison between patients who underwent parenchymal liver resection (n = 42) and matched pairs from group 2 with similar extent of cytoreduction did not yield significant differences in morbidity/mortality. CRC patients from group 1 had poorer median overall survival (45.1 vs. 73.5 months from stage IV diagnosis, P = 0.009).
CONCLUSIONS: Liver involvement denotes high peritoneal carcinomatosis burden, which often requires resection of multiple organs in order to achieve optimal cytoreduction. However, liver resection-related morbidity is low and overall morbidity/mortality rates are comparable to other extensive CRS/HIPEC procedures. J. Surg. Oncol. 2016;113:432-437.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  cytoreductive surgery; hepatectomy; hyperthermic intraperitoneal chemotherapy; liver resection

Mesh:

Substances:

Year:  2016        PMID: 26804119     DOI: 10.1002/jso.24153

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  Therapeutic options for peritoneal metastasis arising from colorectal cancer.

Authors:  Gabriel Glockzin; Hans J Schlitt; Pompiliu Piso
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

2.  Impact of Synchronous Liver Resection on the Perioperative Outcomes of Patients Undergoing CRS-HIPEC.

Authors:  Jordan M Cloyd; Sherif Abdel-Misih; John Hays; Mary E Dillhoff; Timothy M Pawlik; Carl Schmidt
Journal:  J Gastrointest Surg       Date:  2018-04-30       Impact factor: 3.452

3.  Perioperative and Oncological Outcomes of Combined Hepatectomy with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.

Authors:  Mohammad Adileh; Eyal Mor; Arie Ariche; Aviram Nissan; Dan Assaf; Haggai Benvenisti; Shachar Laks; Almog Ben-Yaacov; Gal Schtrechman; David Hazzan; Einat Shacham-Shmueli; Ofer Margalit; Naama Halpern; Dan Aderka; Daria Perelson
Journal:  Ann Surg Oncol       Date:  2020-09-23       Impact factor: 5.344

4.  Clinical outcomes of complete cytoreduction with concurrent liver resection followed by hyperthermic intraperitoneal chemotherapy for synchronous peritoneal and liver metastatic colorectal cancer.

Authors:  Youngbae Jeon; Eun Jung Park; Jin Hong Lim; Seung Hyuk Baik
Journal:  World J Surg Oncol       Date:  2019-12-11       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.